Inventor of synthetic Interferon discusses potential against COVID-19

Pioneering biotech company strengthened by senior appointments to bolster capabilities in research, product development and clinical trials of COVID-19 drug.  Company ready to accelerate the development of Alfacyte™ – ILC’s lead hybrid interferon designed to combat viral infections including COVID-19. ILC is delighted to announce that it has made two

As we live through the most rapidly evolving viral environment the world has seen, there is a critical need for effective and safe antiviral medicines to meet the challenges of today and the inevitable threats of tomorrow. Worldwide, we are searching for ways to inactivate major viruses – from influenza,